share_log

Tonix Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Tonix Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Tonix Pharmaceuticals | PRE 14A：並購重組委托聲明
SEC announcement ·  04/06 04:50
牛牛AI助理已提取核心訊息
Tonix Pharmaceuticals Holding Corp. (Tonix) announced the filing of a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Shareholders. The meeting is scheduled to be held virtually on May 22, 2024, at 11:00 a.m. Eastern Daylight Time. Shareholders of record as of March 25, 2024, are entitled to attend, vote, and ask questions during the meeting. The agenda includes the election of eight director nominees, the ratification of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of a reverse stock split proposal. Additionally, the meeting will address the approval of the repricing of various series of warrants issued in 2023. The proxy materials will be furnished to shareholders on or about April 16, 2024. The company's CEO and Chairman, Seth Lederman, invites shareholders to attend the virtual meeting and emphasizes the importance of voting by proxy if attendance is not possible.
Tonix Pharmaceuticals Holding Corp. (Tonix) announced the filing of a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Shareholders. The meeting is scheduled to be held virtually on May 22, 2024, at 11:00 a.m. Eastern Daylight Time. Shareholders of record as of March 25, 2024, are entitled to attend, vote, and ask questions during the meeting. The agenda includes the election of eight director nominees, the ratification of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of a reverse stock split proposal. Additionally, the meeting will address the approval of the repricing of various series of warrants issued in 2023. The proxy materials will be furnished to shareholders on or about April 16, 2024. The company's CEO and Chairman, Seth Lederman, invites shareholders to attend the virtual meeting and emphasizes the importance of voting by proxy if attendance is not possible.
Tonix Pharmicals Holding Corp.（Tonix）宣佈向美國證券交易委員會（SEC）提交了即將舉行的年度股東大會的初步委託書。該會議定於2024年5月22日美國東部夏令時間上午11點以虛擬方式舉行。截至2024年3月25日的登記股東有權在會議期間出席、投票和提問。該議程包括選舉八名董事候選人，批准EisnerAmper LLP作爲公司截至2024年12月31日的財政年度的獨立註冊會計師事務所，以及批准反向股票拆分提案。此外，會議還將討論批准2023年發行的各種認股權證的重新定價問題。代理材料將在2024年4月16日左右提供給股東。該公司首席執行官兼董事長塞思·萊德曼邀請股東參加虛擬會議，並強調如果無法出席，則由代理人投票的重要性。
Tonix Pharmicals Holding Corp.（Tonix）宣佈向美國證券交易委員會（SEC）提交了即將舉行的年度股東大會的初步委託書。該會議定於2024年5月22日美國東部夏令時間上午11點以虛擬方式舉行。截至2024年3月25日的登記股東有權在會議期間出席、投票和提問。該議程包括選舉八名董事候選人，批准EisnerAmper LLP作爲公司截至2024年12月31日的財政年度的獨立註冊會計師事務所，以及批准反向股票拆分提案。此外，會議還將討論批准2023年發行的各種認股權證的重新定價問題。代理材料將在2024年4月16日左右提供給股東。該公司首席執行官兼董事長塞思·萊德曼邀請股東參加虛擬會議，並強調如果無法出席，則由代理人投票的重要性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。